Skip to content
Tenfell
Awarded contract
Published 11 Aug 2023

NHS London Branded Medicines - Tranche B - September 2023

NHS England · London

Key facts

Awarded
13 Jul 2023
Contract starts
31 Aug 2023
Contract ends
31 Aug 2025
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 36 suppliers

SupplierValue
Takeda UK Limited—
Almirall Ltd—
CST Pharma Ltd—
GlaxoSmithKline—
Janssen-Cilag Ltd—
Orifarm UK—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Abbvie Ltd—
Aventis Pharma Ltd T/A Sanofi—
Sandoz Ltd—
Thornton & Ross Ltd—
Typharm Ltd—
Accord-UK Ltd—
AstraZeneca—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Galapagos Biotech UK Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Kent Pharma Ltd—
Merck Serono Limited—
Merck Sharpe & Dohme (UK) Limited—
Mylan—
Neon Healthcare Ltd—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Organon Pharmaceuticals UK Ltd—
Roche Products Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
Sun Pharma UK Ltd—
UCB Pharma Ltd—
Zentiva Pharma UK Ltd—

Description

NHS London Branded Medicines - Tranche B - September 2023

Offer reference number: CM/PHR/22/5677

CM/PHR/22/5677/01 - NHS Framework for London Branded Medicines - Tranche B. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5677/02 - NHS Framework for London Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.